Browsing by Subject "Transplantation Conditioning"
Now showing items 1-20 of 28
-
A novel reduced-intensity conditioning regimen for unrelated umbilical cord blood transplantation in children with nonmalignant diseases.
(Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014-03)Reduced-intensity conditioning (RIC) regimens have the potential to decrease transplantation-related morbidity and mortality. However, engraftment failure has been prohibitively high after RIC unrelated umbilical cord blood ... -
Allogeneic stem cell transplantation with omidubicel in sickle cell disease.
(Blood advances, 2021-02)Many patients with sickle cell disease (SCD) do not have HLA-matched related donors for hematopoietic stem cell transplantation (HSCT). Unrelated cord blood (UCB) is an alternative graft option but is historically associated ... -
Cell therapy for diverse central nervous system disorders: inherited metabolic diseases and autism.
(Pediatric research, 2018-01)The concept of utilizing human cells for the treatment of medical conditions is not new. In its simplest form, blood product transfusion as treatment of severe hemorrhage has been practiced since the 1800s. The advent of ... -
Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders.
(Bone marrow transplantation, 2021-06)Hematopoietic stem cell transplantation (HCT) has been increasingly used for patients with inherited metabolic disorders (IMD). Immune mediated cytopenias (IMCs) after HCT, manifesting as hemolytic anemia, thrombocytopenia, ... -
Durable Chimerism and Long-Term Survival after Unrelated Umbilical Cord Blood Transplantation for Pediatric Hemophagocytic Lymphohistiocytosis: A Single-Center Experience.
(Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017-10)Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disorder of immune dysregulation characterized by fever, hepatosplenomegaly, cytopenias, central nervous system disease, increased inflammatory markers, and ... -
Durable engraftment and correction of hematological abnormalities in children with congenital amegakaryocytic thrombocytopenia following myeloablative umbilical cord blood transplantation.
(Pediatric transplantation, 2015-11)The use of HSCT is the only potentially curative treatment for CAMT, but access is limited by the availability of suitable donors. We report five consecutive patients with CAMT who received MAC and partially HLA-mismatched, ... -
Effect of cord blood processing on transplantation outcomes after single myeloablative umbilical cord blood transplantation.
(Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015-04)Variations in cord blood manufacturing and administration are common, and the optimal practice is not known. We compared processing and banking practices at 16 public cord blood banks (CBB) in the United States and assessed ... -
Eighth Annual International Umbilical Cord Blood Transplantation Symposium, San Francisco, California, June 3-5, 2010.
(Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011-02) -
Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission.
(Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017-08)For pediatric patients with acute lymphoblastic leukemia (ALL), relapse is an important cause of treatment failure after unrelated cord blood transplant (UCBT). Compared with other donor sources, relapse is similar or even ... -
Gene expression signatures that predict radiation exposure in mice and humans.
(PLoS Med, 2007-04)BACKGROUND: The capacity to assess environmental inputs to biological phenotypes is limited by methods that can accurately and quantitatively measure these contributions. One such example can be seen in the context of exposure ... -
Late Effects after Umbilical Cord Blood Transplantation in Very Young Children after Busulfan-Based, Myeloablative Conditioning.
(Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016-09)Infants and young children who undergo allogeneic cord blood transplantation (CBT) are at increased risk for late effects because of exposure of developing organs to chemotherapy and radiation therapy typically used in transplant ... -
Long-term survival and late deaths after hematopoietic cell transplantation for primary immunodeficiency diseases and inborn errors of metabolism.
(Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012-09)It is uncertain whether late mortality rates after hematopoietic cell transplantation for severe combined immunodeficiency (SCID), non-SCID primary immunodeficiency diseases (non-SCID PIDD), and inborn errors of metabolism ... -
Myeloablative transplantation using either cord blood or bone marrow leads to immune recovery, high long-term donor chimerism and excellent survival in chronic granulomatous disease.
(Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012-09)The curative potential of hematopoietic stem cell transplantation in patients with chronic granulomatous disease depends on availability of a suitable donor, successful donor engraftment, and maintenance of long-term donor ... -
Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation.
(Haematologica, 2014-12)A proportion of patients with aplastic anemia who are treated with immunosuppressive therapy develop clonal hematologic disorders, including post-aplastic anemia myelodysplastic syndrome. Many will proceed to allogeneic ... -
One-unit versus two-unit cord-blood transplantation for hematologic cancers.
(The New England journal of medicine, 2014-10)<h4>Background</h4>Umbilical-cord blood has been used as the source of hematopoietic stem cells in an estimated 30,000 transplants. The limited number of hematopoietic cells in a single cord-blood unit prevents its use in ... -
Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome.
(Pediatric blood & cancer, 2014-06)We report on 27 patients with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) who received allogeneic hematopoietic cell transplantation (HCT) between 2000 and 2009. Seventy-eight percent of patients received ... -
Outcomes after hematopoietic stem cell transplantation for children with I-cell disease.
(Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014-11)Mucolipidosis type II (MLII), or I-cell disease, is a rare but severe disorder affecting localization of enzymes to the lysosome, generally resulting in death before the 10th birthday. Although hematopoietic stem ... -
Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning.
(Blood, 2013-05)We report transplantation outcomes of 258 children with Hurler syndrome (HS) after a myeloablative conditioning regimen from 1995 to 2007. Median age at transplant was 16.7 months and median follow-up was 57 months. The ... -
Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide.
(Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-02)<h4>Purpose</h4>Increasing the number of hematopoietic stem and progenitor cells within an umbilical cord blood (UCB) graft shortens the time to hematopoietic recovery after UCB transplantation. In this study, we assessed ... -
Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery.
(J Hematol Oncol, 2018-03-04)BACKGROUND: The binding of CXCR4 with its ligand (stromal-derived factor-1) maintains hematopoietic stem/progenitor cells (HSPCs) in a quiescent state. We hypothesized that blocking CXCR4/SDF-1 interaction after hematopoietic ...
